1. Zaffiri L. i wsp. History of antibiotics. From salvarsan to cephalosporins, J Invest Surg 2012; 25, 2: 67-77.

2. Versporten A. i wsp. European surveillance of antimicrobial consumpion (ESAC): outpatient cephalosporin use in Europe (1997-2009). J Antimicrob Chemother 2011; 66, Suppl 6: vi25-35.

3. Kuthan R. Cefalosporyny II generacji: cefuroksym sodu i aksetyl cefuroksymu. Lek w Polsce 2014, 3, 6-20.

4. Hryniewicz W. i wsp. Sprawozdanie z realizacji Narodowego Programu Ochrony Antybiotyków. Warszawa, 2011. http://www2.mz.gov.pl/wwwfiles/ ma_struktura/docs/3_szpitpilotaz_20120717.pdf

5. Hryniewicz W., Ozorowski T. Szpitalna Lista antybiotyków. Propozycja kierowana do szpitali. Warszawa, 2011. http://www.antybiotyki.edu.pl/ pdf/szpitalna-lista-antyb-20110617.pdf

6. Yutin N., Galperin MY. A genomic update on clostridial phylogeny: Gramnegative spore formers and other misplaced clostridia. Environ Microbiol 2013; 15(10): 2631-2641.

7. Narodowy Program Ochrony Antybiotyków. Rekomendacje postępowania w pozaszpitalnych zakażeniach układu oddechowego 2010. http://www. antybiotyki.edu.pl/pdf/RekomendacjeA42009.pdf

8. Adam D., Scholz H., Helmerking M. Comparison of short-course (5 day) cefuroxime axetil with a standard 10 day oral penicillin V regimen in the treatment of tonsillopharyngitis. J Antimicrob Chemother 2000; 45 Suppl: 23-30.

9. Mehra S., van Moerkerke M. i wsp. Short course therapy with cefuroxime axetil for group A streptococcal tonsillopharyngitis in children. Pediatr Infect Dis J 1998; 17(6): 452-457.

10. Dinur-Schejter Y., Cohen-Cymberknoh M. i wsp. Antibiotic treatment of children with community-acquired pneumonia: comparison of penicillin or ampicillin versus cefuroxime. Pediatr Pulmonol 2013; 48(1): 52-58.

11. Kabra SK., Lodha R., Pandey RM. Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst Rev 2010; 3: CD004874. doi: 10.1002/14651858.CD004874.pub3

12. Yolba I., Tekin R. i wsp. Community-acquired urinary tract infections in children: pathogens, antibiotic susceptibility and seasonal changes. Eur Rev Med Pharmacol Sci 2013; 17(7): 971-976.

13. de Lucas Collantes C., Cela Alvargonzalez J. i wsp. Urinary tract infections: antibiotic resistance and clinical follow up, An Pediatr (Barc) 2012; 76(4): 224-228.

14. Meury SN., Erb T. i wsp. Randomized, comparative efficacy trial of oral penicillin versus cefuroxime for perianal streptococcal dermatitis in children. J Pediatr 2008; 153(6): 799-802.

15. Yoon HI., Lee CH. i wsp. Efficacy of levofloxacin versus cefuroxime in treating acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013; 8:329-334.

16. Magliano E., Grazioli V. i wsp. Gender and age-dependent etiology of community-acquired; urinary tract infections; ScientificWorldJournal 2012; 2012:349597. doi: 10.1100/2012/349597.

17. Prais D., Straussberg R. i wsp. Bacterial susceptibility to oral antibiotics in community acquired urinary tract infection. Arch Dis Child 2003; 88(3): 215-218.

18. Carlier M., Noë M. i wsp. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures. J Antimicrob Chemother 2014; 69(10): 2797-803.

19. Narodowy Program Ochrony Antybiotyków. Profilaktyka, diagnostyka i terapia zakażeń w ortopedii. http://www.antybiotyki.edu.pl/pdf/profilaktykadiagnostykaterapia25_ 11.indd.pdf

20. Ketterl R., Wittwer W. Possibilities for the use of the basic cephalosporin cefuroxime in bone surgery. Tissue levels, effectiveness and tolerance. Infection 1993;

21 Suppl 1: S21-S27. 21. Mathur P., Trikha V. i wsp. Implementation of a short course of prophylactic antibiotic treatment for prevention of postoperative infections in clean orthopaedic surgeries. Indian J Med Res 2013; 137(1): 111-116.